2025 Q4 -tulosraportti
Vain PDF
116 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenNew week is coming up - exciting as always. Let's keep it objective, Don't trash talk. Tone it down instead of resorting to personal attacks. Don't oversell yesterday's news! There's a lot of good in this forum, but the arguing we sometimes see is just too silly. Good luck with your stock market week 😊
The Facebook group seems extremely "behind the curve", doesn't it? Often posts news 2-3 days after publication, and discusses old updates. No offense intended, mind you - but little matches this forum, for better or worse.- ·13 t sitten · MuokattuCAR-T Has anyone seen the program on this? This is not ESGCT in October. "In-vivo CAR seems to have advanced significantly. At RNA Leaders USA on September 25, Circio has received its own 25-minute presentation with the very specific title «Advancing circRNA expression systems applied to in vivo CAR cell Therapy». Circio's own calendar mainly states only that they are participating in the conference; the detailed program reveals what they will actually present. It is a clear indication, but not proof, of a more mature data package"
Excuse me, but what you write is over-interpretation and pure speculation. To believe that a small 25 min presentation means that Circio is sitting on a "commercial breakthrough" or a "more mature data package", is inherently unreasonable when one looks at who else is there. There is nothing in the allocation of this speaking time itself that indicates that Circio's data package is a notch sharper or more mature than what, for example, Circurna or Amrixa will present. To claim otherwise before the numbers are actually on the table, is to deceive oneself. Circular RNA (circRNA) is one of the main themes of the entire conference. Circio is by no means unique here; they are just one of many players who will pitch their platform. If speaking time is proof of "mature data", what then about these competitors who are also working with circular RNA and will present at the same conference? Circurna: Their CEO, Peter Weinstein, has exactly the same type of slot of 25 minutes on September 25 (at 09:50). The title of his presentation is "Harnessing circRNA therapeutics for durable og tolerable treatments...". This is directly competing technology, and the program explicitly states that he will present preclinical data. Amrixa Pharmaceuticals: The company's CEO, Bakhtyar Ali, is also on the speaker list. They are heavily involved with circRNA for rare metabolic diseases. ParcelBio: Their CEO David Weinberg, an authority who previously led the development of circRNA platforms at Orbital Therapeutics, will also speak. In addition, the conference has allocated time for a dedicated panel debate which is exactly called "Circular RNA - The Next Frontier in RNA Therapeutics". - 6 t sittenTämä julkaisu on poistettu.This is bullshit, based on speculation and technological incompetence. Firstly, CAR-T is nothing new.. That more are now trying in vivo CAR-T is expected, but your major fallacy lies in the RNA technology itself. RiboX uses artificial (synthetic) circRNA which must be produced and circularized in a factory, and it is difficult to scale up and purify (CMC). In addition, RNA degrades, which means the effect wanes and requires repeated doses. Circio's circVec is not pre-made circRNA, but a DNA recipe. Our own cells produce our own circRNA from the inside, which provides a completely different and more long-lasting expression. This is what makes Circio an investment case.. That RiboX gets IND factory-made RNA and an RNA-specific LNP, does not change this The two companies utilize the technology in fundamentally different ways, and face completely different challenges. I naturally hope that Circio's method works, but we don't know that yet.. That's why we are waiting for readouts.
·1 päivä sittenI tried to find out who sold aggressively on August 5. Since then, I have collected data on the 300 largest shareholders in Circio. My plan was to write a small program that could show the difference in transactions between two days for individual shareholders. Before I managed to write the program, however, I identified one of those who sold/lent: A single person had sold/lent out more than 1.6 million shares. I am unsure if it is legal to reveal who the person is. So I will not do it now.
It makes no fundamental difference, but I find it interesting to know what is happening on the ownership side.- ·1 päivä sitten · MuokattuCIRCIO – shareholder register 29.07 → 07.08 I have compiled the registrations from 29.07 to 07.08, and there are some movements I think are worth following further. This is not proof of buy/sell, but the pattern is interesting. Nordnet Liv – clear ping-pong 8,095m → 7,693m → 7,569m → 7,500m → 8,109m → 8,202m → 7,281m → 7,382m So from 8,095m to 7,382m in total, but with enormous movements both ways along the way. 04.08: +609k 06.08: −921k 07.08: +101k This is difficult to interpret as usual net buy/sell alone. J.P. Morgan SE – perhaps the most interesting 352 962 → 241 483 → 357 760 → 357 760 → 421 097 → 421 097 → 1 072 683 From 29.07 to 07.08 there is an increase of as much as 719 721 shares. On 07.08 there are two separate JPM SE entries: 660 000 412 683 Total 1 072 683 shares. At the same time, J.P. Morgan Securities PLC has moved: 655 968 → 639 432 → 678 500 → 709 484 → 711 862 → 723 964 → 778 917 There is an increase of 122 949 shares from 29.07 to 07.08. BNY Mellon When the visible BNY entries are summed: 29.07: ~3,14m 30.07: ~2,86m 31.07: ~2,68m 03.08: ~2,60m 04.08: ~2,54m 05.08: ~3,59m 06.08: ~3,19m 07.08: ~2,81m Here we are talking about around 1 million shares up and down in a short time. That is precisely why I would not have used BNY alone as a buy indicator. BofA is also interesting 29.07: 1 146 110 30.07: 224 712 There is a reduction of 921 398 shares. On 05.08 BofA reappeared with 358 216 shares, i.e. +133 504 from 30.07, before the entry again disappeared from the top 100. Goldman 480 479 → 459 665 → 366 366 Net −114 113 shares. Nordnet Bank 13,663m → 13,684m → 13,574m → 13,527m → 13,547m → 13,611m → 13,658m → 13,790m From 29.07 to 07.08: +127 274 shares Interestingly enough, Nordnet Bank has thus increased its holdings again after the drop around 30.07–03.08. What I find interesting now We have several large American custody/broker accounts that are moving strongly: BofA ↓ JPM SE ↑ JPM Securities ↑ BNY ↕ Goldman ↓ Nordnet ↑ I would therefore pay special attention to whether we get a sequence going forward like: BofA ↓ → BNY/JPM ↑ → Nordnet ↑ within 1–3 registration days. If this happens multiple times, it becomes much more interesting. Then we can start to see a pattern where shares seem to be moved through different manager/custody accounts, instead of each individual change representing an actual buy or sell in the market. But important: the register alone cannot tell us if it is a buy, sell, loan, or internal depot movements. Right now, JPM SE at 1,073m shares is the entry I would follow most closely. Next registrations could be quite interesting. This is taken from the top 100 list. Private individuals are not included.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
116 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenNew week is coming up - exciting as always. Let's keep it objective, Don't trash talk. Tone it down instead of resorting to personal attacks. Don't oversell yesterday's news! There's a lot of good in this forum, but the arguing we sometimes see is just too silly. Good luck with your stock market week 😊The Facebook group seems extremely "behind the curve", doesn't it? Often posts news 2-3 days after publication, and discusses old updates. No offense intended, mind you - but little matches this forum, for better or worse.
- ·13 t sitten · MuokattuCAR-T Has anyone seen the program on this? This is not ESGCT in October. "In-vivo CAR seems to have advanced significantly. At RNA Leaders USA on September 25, Circio has received its own 25-minute presentation with the very specific title «Advancing circRNA expression systems applied to in vivo CAR cell Therapy». Circio's own calendar mainly states only that they are participating in the conference; the detailed program reveals what they will actually present. It is a clear indication, but not proof, of a more mature data package"Excuse me, but what you write is over-interpretation and pure speculation. To believe that a small 25 min presentation means that Circio is sitting on a "commercial breakthrough" or a "more mature data package", is inherently unreasonable when one looks at who else is there. There is nothing in the allocation of this speaking time itself that indicates that Circio's data package is a notch sharper or more mature than what, for example, Circurna or Amrixa will present. To claim otherwise before the numbers are actually on the table, is to deceive oneself. Circular RNA (circRNA) is one of the main themes of the entire conference. Circio is by no means unique here; they are just one of many players who will pitch their platform. If speaking time is proof of "mature data", what then about these competitors who are also working with circular RNA and will present at the same conference? Circurna: Their CEO, Peter Weinstein, has exactly the same type of slot of 25 minutes on September 25 (at 09:50). The title of his presentation is "Harnessing circRNA therapeutics for durable og tolerable treatments...". This is directly competing technology, and the program explicitly states that he will present preclinical data. Amrixa Pharmaceuticals: The company's CEO, Bakhtyar Ali, is also on the speaker list. They are heavily involved with circRNA for rare metabolic diseases. ParcelBio: Their CEO David Weinberg, an authority who previously led the development of circRNA platforms at Orbital Therapeutics, will also speak. In addition, the conference has allocated time for a dedicated panel debate which is exactly called "Circular RNA - The Next Frontier in RNA Therapeutics".
- 6 t sittenTämä julkaisu on poistettu.This is bullshit, based on speculation and technological incompetence. Firstly, CAR-T is nothing new.. That more are now trying in vivo CAR-T is expected, but your major fallacy lies in the RNA technology itself. RiboX uses artificial (synthetic) circRNA which must be produced and circularized in a factory, and it is difficult to scale up and purify (CMC). In addition, RNA degrades, which means the effect wanes and requires repeated doses. Circio's circVec is not pre-made circRNA, but a DNA recipe. Our own cells produce our own circRNA from the inside, which provides a completely different and more long-lasting expression. This is what makes Circio an investment case.. That RiboX gets IND factory-made RNA and an RNA-specific LNP, does not change this The two companies utilize the technology in fundamentally different ways, and face completely different challenges. I naturally hope that Circio's method works, but we don't know that yet.. That's why we are waiting for readouts.
- ·1 päivä sittenI tried to find out who sold aggressively on August 5. Since then, I have collected data on the 300 largest shareholders in Circio. My plan was to write a small program that could show the difference in transactions between two days for individual shareholders. Before I managed to write the program, however, I identified one of those who sold/lent: A single person had sold/lent out more than 1.6 million shares. I am unsure if it is legal to reveal who the person is. So I will not do it now.It makes no fundamental difference, but I find it interesting to know what is happening on the ownership side.
- ·1 päivä sitten · MuokattuCIRCIO – shareholder register 29.07 → 07.08 I have compiled the registrations from 29.07 to 07.08, and there are some movements I think are worth following further. This is not proof of buy/sell, but the pattern is interesting. Nordnet Liv – clear ping-pong 8,095m → 7,693m → 7,569m → 7,500m → 8,109m → 8,202m → 7,281m → 7,382m So from 8,095m to 7,382m in total, but with enormous movements both ways along the way. 04.08: +609k 06.08: −921k 07.08: +101k This is difficult to interpret as usual net buy/sell alone. J.P. Morgan SE – perhaps the most interesting 352 962 → 241 483 → 357 760 → 357 760 → 421 097 → 421 097 → 1 072 683 From 29.07 to 07.08 there is an increase of as much as 719 721 shares. On 07.08 there are two separate JPM SE entries: 660 000 412 683 Total 1 072 683 shares. At the same time, J.P. Morgan Securities PLC has moved: 655 968 → 639 432 → 678 500 → 709 484 → 711 862 → 723 964 → 778 917 There is an increase of 122 949 shares from 29.07 to 07.08. BNY Mellon When the visible BNY entries are summed: 29.07: ~3,14m 30.07: ~2,86m 31.07: ~2,68m 03.08: ~2,60m 04.08: ~2,54m 05.08: ~3,59m 06.08: ~3,19m 07.08: ~2,81m Here we are talking about around 1 million shares up and down in a short time. That is precisely why I would not have used BNY alone as a buy indicator. BofA is also interesting 29.07: 1 146 110 30.07: 224 712 There is a reduction of 921 398 shares. On 05.08 BofA reappeared with 358 216 shares, i.e. +133 504 from 30.07, before the entry again disappeared from the top 100. Goldman 480 479 → 459 665 → 366 366 Net −114 113 shares. Nordnet Bank 13,663m → 13,684m → 13,574m → 13,527m → 13,547m → 13,611m → 13,658m → 13,790m From 29.07 to 07.08: +127 274 shares Interestingly enough, Nordnet Bank has thus increased its holdings again after the drop around 30.07–03.08. What I find interesting now We have several large American custody/broker accounts that are moving strongly: BofA ↓ JPM SE ↑ JPM Securities ↑ BNY ↕ Goldman ↓ Nordnet ↑ I would therefore pay special attention to whether we get a sequence going forward like: BofA ↓ → BNY/JPM ↑ → Nordnet ↑ within 1–3 registration days. If this happens multiple times, it becomes much more interesting. Then we can start to see a pattern where shares seem to be moved through different manager/custody accounts, instead of each individual change representing an actual buy or sell in the market. But important: the register alone cannot tell us if it is a buy, sell, loan, or internal depot movements. Right now, JPM SE at 1,073m shares is the entry I would follow most closely. Next registrations could be quite interesting. This is taken from the top 100 list. Private individuals are not included.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
116 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenNew week is coming up - exciting as always. Let's keep it objective, Don't trash talk. Tone it down instead of resorting to personal attacks. Don't oversell yesterday's news! There's a lot of good in this forum, but the arguing we sometimes see is just too silly. Good luck with your stock market week 😊The Facebook group seems extremely "behind the curve", doesn't it? Often posts news 2-3 days after publication, and discusses old updates. No offense intended, mind you - but little matches this forum, for better or worse.
- ·13 t sitten · MuokattuCAR-T Has anyone seen the program on this? This is not ESGCT in October. "In-vivo CAR seems to have advanced significantly. At RNA Leaders USA on September 25, Circio has received its own 25-minute presentation with the very specific title «Advancing circRNA expression systems applied to in vivo CAR cell Therapy». Circio's own calendar mainly states only that they are participating in the conference; the detailed program reveals what they will actually present. It is a clear indication, but not proof, of a more mature data package"Excuse me, but what you write is over-interpretation and pure speculation. To believe that a small 25 min presentation means that Circio is sitting on a "commercial breakthrough" or a "more mature data package", is inherently unreasonable when one looks at who else is there. There is nothing in the allocation of this speaking time itself that indicates that Circio's data package is a notch sharper or more mature than what, for example, Circurna or Amrixa will present. To claim otherwise before the numbers are actually on the table, is to deceive oneself. Circular RNA (circRNA) is one of the main themes of the entire conference. Circio is by no means unique here; they are just one of many players who will pitch their platform. If speaking time is proof of "mature data", what then about these competitors who are also working with circular RNA and will present at the same conference? Circurna: Their CEO, Peter Weinstein, has exactly the same type of slot of 25 minutes on September 25 (at 09:50). The title of his presentation is "Harnessing circRNA therapeutics for durable og tolerable treatments...". This is directly competing technology, and the program explicitly states that he will present preclinical data. Amrixa Pharmaceuticals: The company's CEO, Bakhtyar Ali, is also on the speaker list. They are heavily involved with circRNA for rare metabolic diseases. ParcelBio: Their CEO David Weinberg, an authority who previously led the development of circRNA platforms at Orbital Therapeutics, will also speak. In addition, the conference has allocated time for a dedicated panel debate which is exactly called "Circular RNA - The Next Frontier in RNA Therapeutics".
- 6 t sittenTämä julkaisu on poistettu.This is bullshit, based on speculation and technological incompetence. Firstly, CAR-T is nothing new.. That more are now trying in vivo CAR-T is expected, but your major fallacy lies in the RNA technology itself. RiboX uses artificial (synthetic) circRNA which must be produced and circularized in a factory, and it is difficult to scale up and purify (CMC). In addition, RNA degrades, which means the effect wanes and requires repeated doses. Circio's circVec is not pre-made circRNA, but a DNA recipe. Our own cells produce our own circRNA from the inside, which provides a completely different and more long-lasting expression. This is what makes Circio an investment case.. That RiboX gets IND factory-made RNA and an RNA-specific LNP, does not change this The two companies utilize the technology in fundamentally different ways, and face completely different challenges. I naturally hope that Circio's method works, but we don't know that yet.. That's why we are waiting for readouts.
- ·1 päivä sittenI tried to find out who sold aggressively on August 5. Since then, I have collected data on the 300 largest shareholders in Circio. My plan was to write a small program that could show the difference in transactions between two days for individual shareholders. Before I managed to write the program, however, I identified one of those who sold/lent: A single person had sold/lent out more than 1.6 million shares. I am unsure if it is legal to reveal who the person is. So I will not do it now.It makes no fundamental difference, but I find it interesting to know what is happening on the ownership side.
- ·1 päivä sitten · MuokattuCIRCIO – shareholder register 29.07 → 07.08 I have compiled the registrations from 29.07 to 07.08, and there are some movements I think are worth following further. This is not proof of buy/sell, but the pattern is interesting. Nordnet Liv – clear ping-pong 8,095m → 7,693m → 7,569m → 7,500m → 8,109m → 8,202m → 7,281m → 7,382m So from 8,095m to 7,382m in total, but with enormous movements both ways along the way. 04.08: +609k 06.08: −921k 07.08: +101k This is difficult to interpret as usual net buy/sell alone. J.P. Morgan SE – perhaps the most interesting 352 962 → 241 483 → 357 760 → 357 760 → 421 097 → 421 097 → 1 072 683 From 29.07 to 07.08 there is an increase of as much as 719 721 shares. On 07.08 there are two separate JPM SE entries: 660 000 412 683 Total 1 072 683 shares. At the same time, J.P. Morgan Securities PLC has moved: 655 968 → 639 432 → 678 500 → 709 484 → 711 862 → 723 964 → 778 917 There is an increase of 122 949 shares from 29.07 to 07.08. BNY Mellon When the visible BNY entries are summed: 29.07: ~3,14m 30.07: ~2,86m 31.07: ~2,68m 03.08: ~2,60m 04.08: ~2,54m 05.08: ~3,59m 06.08: ~3,19m 07.08: ~2,81m Here we are talking about around 1 million shares up and down in a short time. That is precisely why I would not have used BNY alone as a buy indicator. BofA is also interesting 29.07: 1 146 110 30.07: 224 712 There is a reduction of 921 398 shares. On 05.08 BofA reappeared with 358 216 shares, i.e. +133 504 from 30.07, before the entry again disappeared from the top 100. Goldman 480 479 → 459 665 → 366 366 Net −114 113 shares. Nordnet Bank 13,663m → 13,684m → 13,574m → 13,527m → 13,547m → 13,611m → 13,658m → 13,790m From 29.07 to 07.08: +127 274 shares Interestingly enough, Nordnet Bank has thus increased its holdings again after the drop around 30.07–03.08. What I find interesting now We have several large American custody/broker accounts that are moving strongly: BofA ↓ JPM SE ↑ JPM Securities ↑ BNY ↕ Goldman ↓ Nordnet ↑ I would therefore pay special attention to whether we get a sequence going forward like: BofA ↓ → BNY/JPM ↑ → Nordnet ↑ within 1–3 registration days. If this happens multiple times, it becomes much more interesting. Then we can start to see a pattern where shares seem to be moved through different manager/custody accounts, instead of each individual change representing an actual buy or sell in the market. But important: the register alone cannot tell us if it is a buy, sell, loan, or internal depot movements. Right now, JPM SE at 1,073m shares is the entry I would follow most closely. Next registrations could be quite interesting. This is taken from the top 100 list. Private individuals are not included.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt